Phase i dose-escalation study of LCL161, an oral inhibitorof apoptosis proteins inhibitor, in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3103-3110

  Infante, Jeffrey R ^a   Dees, E Claire ^b   Olszanski, Anthony J ^c   Dhuria, Shyeilla V ^e   Sen, Suman ^e   Cameron, Scott ^f   Cohen, Roger B ^d  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INHIBITOR OF APOPTOSIS PROTEIN; LCL 161; UNCLASSIFIED DRUG; CYTOKINE; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; SOLUTION AND SOLUBILITY; TABLET; THIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CYTOKINE RELEASE SYNDROME; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SOLUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; RAT; SOLID TUMOR; TABLET; VOMITING; BIOAVAILABILITY; CHEMICALLY INDUCED; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; SECRETION (PROCESS); SOLUTION AND SOLUBILITY; SYNDROME; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOKINES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PHARMACEUTICAL SOLUTIONS; SYNDROME; TABLETS; THIAZOLES; TREATMENT OUTCOME; VOMITING;

EID: 84907883684     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.3993     Document Type: Article

References (27)

1. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
2. Shiraki K, Sugimoto K, Yamanaka Y, et al: Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med 12:705-708, 2003
3. Tamm I, Kornblau SM, Segall H, et al: Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796-1803, 2000
4. Tamm I, Richter S, Oltersdorf D, et al: High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 10:3737-3744, 2004
5. Gyrd-Hansen M, Meier P: IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10:561-574, 2010
6. Hunter AM, LaCasse EC, Korneluk RG: The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12:1543-1568, 2007
7. Deveraux QL, Takahashi R, Salvesen GS, et al: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-304, 1997
8. Vince JE, Wong WW, Khan N, et al: IAP antagonists target cIAP1 to induce TNFalphadependent apoptosis. Cell 131:682-693, 2007
9. Paquette N, Broemer M, Aggarwal K, et al: Caspase-mediated cleavage, IAP binding, and ubiquitination: Linking three mechanisms crucial for Drosophila NF-kappaB signaling. Mol Cell 37:172-182, 2010
10. Hu S, Yang X: Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem 278:10055-10060, 2003
11. Du C, Fang M, Li Y, et al: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell102:33-42, 2000
12. Flygare JA, Beresini M, Budha N, et al: Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 55:4101-4113, 2012
13. Fulda S, Vucic D: Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11:109-124, 2012
14. Li L, Thomas RM, Suzuki H, et al: A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305:1471-1474, 2004
15. Firestone B, Conway C, Yang G, et al: Correlation between TNF-α and LCL161 anti-tumor activity in patient derived xenograft models of human cancer. Mol Cancer Ther 8, 2009 (suppl; abstr B27)
16. Ma WW, Zhang H, Hylander B, et al: TL32711, a novel smac mimetic, exerts significant antitumor efficacy in primary adenocarcinoma model. Cancer Res 72, 2012 (suppl; abst 1939)
17. Cai Q, Sun H, Peng Y, et al: A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 54: 2714-2726, 2011
18. Humphreys RC, Poortman C, McCormick K, et al: A novel combination of a small molecule IAP inhibitor and a TRAIL-R1 monoclonal antibody synergize to induce apoptosis in pancreatic tumor cell lines. Mol Cancer Ther 8, 2009 (suppl; abstr C10)
19. Zawel LS, Straub C, Firestone B, et al: Therapeutic targeting of inhibitor of apoptosis proteins. Cancer Res 70, 2010 (suppl; abstr 138)
20. Neuenschwander B, Branson M, Gsponer T: Critical aspects of the bayesian approach to phase I cancer trials. Stat Med 27:2420-2439, 2008
21. Smith BP, Vandenhende FR, DeSante KA, et al: Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278-1283, 2000
22. Allensworth JL, Sauer SJ, Lyerly HK, et al: Smac mimetic birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α- independent mechanism. Breast Cancer Res Treat 137:359-371, 2013
23. Graham MA, Mitsuuchi Y, Burns J, et al: Phase 1 PK/PD analysis of the smac-mimetic TL32711 demonstrates potent and sustained cIAP suppression in patient PBMCs and tumor biopsies.Mol Cancer Ther 10, 2011 (suppl; abstr A25)
24. Amaravadi RK, Senzer NN, Martin LP, et al: A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. J Clin Oncol 31:142s, 2013 (suppl; abstr 2504)
25. Wong H, Gould SE, Budha N, et al: Learning and confirming with preclinical studies: Modeling and simulation in the discovery of GDC-0917, aninhibitor of apoptosis proteins antagonist. Drug Metab Dispos, 41:2104-2113, 2013
26. Tolcher AW, Papadopoulos, KP, Patnaik, A, et al: Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. J Clin Oncol 31: 141s, 2013 (suppl; abstr 2503)
27. Sikic BI, Eckhardt SG, Gallant, HA, et al: Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. J Clin Oncol 29:196s, 2011 (suppl; abstract 3008)